Chronic obstructive pulmonary disease international guidelines

Current Opinion in Pulmonary Medicine

Volumn 4, Issue 2, 1998, Pages 76-84

  Fabbri, Leonardo ^a   Caramori, Gaetano ^a   Beghe, Bianca ^a   Papi, Alberto ^a   Ciaccia, Adalberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; HUMAN; INTERNATIONAL COOPERATION; ITALY; MALE; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PULMONOLOGY; REVIEW; STANDARD;

FEMALE; HUMANS; INTERNATIONAL COOPERATION; ITALY; LUNG DISEASES, OBSTRUCTIVE; MALE; PRACTICE GUIDELINES; PULMONARY DISEASE (SPECIALTY); SOCIETIES, MEDICAL;

EID: 0032013924     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199803000-00004     Document Type: Review

References (126)

1. Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR, for the CAEP/CTS Asthma Advisory Committee: Guidelines for the emergency management of asthma in adults. Can Med Assoc J 1996, 155:25-37.
2. The British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, the National Asthma Campaign: Guidelines for management of asthma in adults: I: chronic persistent asthma. BMJ 1990, 301:651-653.
3. The British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, the National Asthma Campaign: Guidelines for management of asthma in adults: II: acute severe asthma. BMJ 1990, 301:797-800.
4. The British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group: Guidelines for the management of asthma. Thorax 1993, 48:S1-S24.
5. The British Thoracic Society, the National Asthma Campaign, the Royal College of Physicians of London in association with the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, the British Paediatric Respiratory Society, and the Royal College of Paediatrics and Child Health: The British guidelines on asthma management: 1995 review and position statement. Thorax 1997, 52(suppl 1):1-21.
6. National Asthma Education and Prevention Program: Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; National Heart, Lung and Blood Institute; 1997. publication no. 97-4051 A.
7. Ernst P, Fitzgerald JM, Spier S: Canadian asthma consensus conference summary of recommendations. Can Respir J 1996, 3:89-100.
8. Hargreave FE, Dolovich J, Newhouse MT: The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990, 85:1098-1111.
9. Sheffer AL, ed: International consensus report on diagnosis and management of asthma. [National Institute of Health publication no. 92-3091]. Eur Respir J 1992, 5:601-641.
10. Sheffer AL, ed: Global Initiative for Asthma. National Heart, Lung and Blood Institute/World Health Organization Workshop Report. Bethesda, MD: National Institutes of Health; National Heart, Lung and Blood Institute. Publication no. 95-3659; 1995.
11. Woolcock AJ, Rubinfield A, Seale P: The Australian asthma management plan. Med J Aust 1989, 151:650-653.
12. Canadian Thoracic Society Workshop Group: Guidelines for the assessment and management of chronic obstructive pulmonary disease. Can Med Assoc J 1992, 147:420-428.
13. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987, 136:225-244.
14. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J, on behalf of the Task Force: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1398-1420.
15. Jenkins C, Mitchell C, Irving L, Frith P, Young I, for the Thoracic Society of Australia and New Zealand: Guidelines for the management of chronic obstructive pulmonary disease. Mod Med Aust 1995, 38:132-146.
16. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, Braman S, Olsen G, Philips Y: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152(suppl):77-120.
17. The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society: BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997, 52(suppl 5):1-28. The BTS consensus document on the diagnosis and treatment of COPD.
18. Anthonisen N: Epidemiology and the Lung Health Study. Eur Respir Rev 1997, 7:202-205.
19. Lancet: From what will we die in 2020? [editorial]. Lancet 1997, 349:1263.
20. Ernster VL, Colford JM Jr: Host and disease: influence of demographic and socioeconomic factors. In Harrison's Principles of Internal Medicine, edn 14. Edited by Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. New York: McGraw-Hill; 1997:14-18.
21. Fiel SB: Chronic obstructive pulmonary disease mortality and mortality reduction. Drugs 1996, 52(suppl 2):55-61.
22. Petty TL, Weinmann GG: Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease: National Heart, Lung and Blood Institute workshop summary. JAMA 1997, 277:246-253.
23. Tirimanna PR, van Schayck CP, den Otter JJ, van Weel C, van Herwaarden CL, van den Boom G, van Grunsven PM, van den Bosch WJ: Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? Br J Gen Pract 1996, 46:277-281.
24. Desideri M, Viegi G, Carrozzi L, Pedreschi M, Pistelli F, Maggiorelli F, Fornai E, Paoletti P, Giuntini C: Mortality rates for respiratory disorders in Italy (1979-1990). Monaldi Arch Chest Dis 1997, 52:212-216.
25. Fuso L, Incalzi RA, Pistilli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G: Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995, 98:272-277.
26. Seneff MG, Douglas P, Wagner P, Wagner RP, Zimmerman JE, Knaus A: Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995, 274:1852-1857.
27. Lofdahl C-G: Cost development of obstructive airway disease in Sweden. Eur Respir Rev 1996, 6:113-115.
28. Vermeire P: Guidelines on the management of COPD. Eur Respir Rev 1997, 7:227-229.
29. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows: report of the Working Party, Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J 1993, 6(suppl 16):5-40.
30. Fletcher CM, Pride NB: Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax 1984, 39:81-85.
31. Kerstjens HAM, Brand PLP, Postma DS: Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 154(suppl):266-272.
32. Medical Research Council Committee on the Aetiology of Chronic Bronchitis: Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965, i:775-779.
33. Snider GL, Kleinerman J, Thurlbeck WM, Bengali ZH: The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of Lung Diseases, workshop. Am Rev Respir Dis 1985, 132:182-185.
34. Eda S, Kubo K, Fujimoto K, Matsuzawa Y, Sekiguchi M, Sakai F: The relations between expiratory chest CT using helical CT and pulmonary function tests in emphysema. Am J Respir Crit Care Med 1997, 155:1290-1294.
35. Gevenois PA, de Maertelaer V, de Vuyst PD, Zanen J, Yernault J-C: Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1995, 152:653-657.
36. Gevenois PA, de Vuyst PD, de Maertelaer V, Zanen J, Jacobovitz D, Cosio MG, Yernault J-C: Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996, 154:187-192.
37. Miniati M, Filippi E, Falaschi F, Carrozzi L, Milne NC, Sostman HD, Pistolesi M: Radiologic evaluation of emphysema in patients with chronic obstructive pulmonary disease: chest radiography versus high resolution computed tomography. Am J Respir Crit Care Med 1995, 151:1359-1367.
38. Uppaluri R, Mitsa T, Sonka M, Hoffman EA, McLennan G: Quantification of pulmonary emphysema from lung computed tomography images. Am J Respir Crit Care Med 1997, 156:248-254.
39. Sterk PJ, Fabbri LM, Quanjer PhH, Cockroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo J-L: Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults: report of the Working Party, Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J 1993, 6(suppl 16):53-83.
40. Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP, Wise RA: Gender difference in airway hyperresponsiveness in smokers with mild COPD. Am J Respir Crit Care Med 1994, 150:956-961.
41. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI: Intraluminal airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989, 140:1527-1537.
42. Connors AF, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA for the SUPPORT Investigators: Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996, 154:959-967.
43. Jeffery PK: Pathology of asthma and COPD: a synopsis. Eur Respir Rev 1997, 7:111-118. COPD is compared with asthma pathology in this paper written by a known expert.
44. Saetta M: Airway pathology of COPD compared with asthma. Eur Respir Rev 1997, 7:29-33. Beautiful, clear comparison between COPD and asthma pathology written by another expert in the field.
45. Saetta M, Di Stefano A, Turato G, Maestrelli P, Mapp CE, Ruggeri MP, Roggeri A, Boschetto P, Fabbri LM: Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996, 153:629-632.
46. O'Shaughness TC, Ansari TW, Barnes NC, Jeffery PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997, 155:852-857.
47. Piattella M, Maestrelli P, Saetta M, Mapp C, Caramori G, Ciaccia A, Fabbri LM: Sputum eosinophilia during mild exacerbations and Sputum neutrophilia during severe exacerbations of COPD [abstract]. Am J Respir Crit Care Med 1996, 153(suppl):A822.
48. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, Bousquet J: Corticosteroid's reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997, 155:1529-1534.
49. Sandford AJ, Weir TD, Paré PD: Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997, 10:1380-1391. The best review available on the genetics of COPD.
50. Buist AS: Risk factors for COPD. Eur Respir Rev 1996, 6:253-258. Concise, clearly written review on risk factors for COPD.
51. Senior RM, Shapiro SD: Chronic obstructive pulmonary disease: epidemiology, pathophysiology and pathogenesis. In Fishman's Pulmonary Diseases and Disorders, edn 3. Edited by Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM. New York: McGraw-Hill; 1997:659-681.
52. Doll R, Peto R, Wheatley K, Gray R, Sutherland I: Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994, 309:901-911.
53. Fielding JE: Smoking: health effects and control. N Engl J Med 1995, 313:491-498.
54. Law MR, Hackshaw AK: Environmental tobacco smoke. Br Med Bull 1996, 52:22-34.
55. Hendrick DJ: Occupation and chronic obstructive pulmonary disease. Thorax 1996, 51:947-955.
56. Dimich-Ward H, Kennedy SM, Chan-Yeung M: Occupational exposures and chronic airflow limitation. Can Respir J 1996, 3:133-140.
57. Dalphin JC: La bronchite chronique obstructive (BCO) en milieu agricole fourrager. Rev Mal Respir 1996, 13:575-581.
58. Senthilsevan A, Dosman JA, Kirychuk SP, Barber EM, Rhodes CS, Zhang Y, Hurst TS: Accelerated lung function decline in swine confinement workers. Chest 1997, 111:1733-1741.
59. Pedersen B, Iversen M, Bundgaard Larsen B, Dahl R: Pig farmers have signs of bronchial inflammation and increased numbers of lymphocytes and neutrophils in BAL fluid. Eur Respir J 1996, 9:524-530.
60. Aguayo SM: Determinants of susceptibility to cigarette smoke: potential roles for neuroendocrine cells and neuropeptides in airway inflammation, airway wall remodeling, and chronic airflow obstruction. Am J Respir Crit Care Med 1994, 149:1692-1698.
61. Mapp CM, Lucchini RE, Facchini F, Turato G, Saetta M, Caramori G, Ciaccia A, Maestrelli P, Springall DR, Polak JM, Fabbri LM: Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med 1997, 156:1963-1968.
62. Keatings VM, Barnes PJ: Comparison of inflammatory cytokines in chronic obstructive pulmonary disease, asthma and controls. Eur Respir Rev 1997, 7:146-150.
63. Knight KR, Burdon JGW, Cook L, Brenton S, Ayad M, Janus ED: The proteinase-antiproteinase theory of emphysema: a speculative analysis of recent advances in the pathogenesis of emphysema. Respirology 1997, 2:91-95.
64. Tetley TD: Matrix metalloproteinases: a role in emphysema? Thorax 1997, 52:495.
65. Finlay GA, Russell KJ, McMahon KJ, D'Arcy EM, Masterson JB, Fitzgerald MX, O'Connor CM: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997, 52:502-506.
66. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, Fitzgerald MX, O'Connor CM: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997, 156:240-247.
67. Jones AT, Evans TW: NO: COPD and beyond. Thorax 1997, 52(suppl 3):16-21.
68. Rennard S: Pathophysiological mechanisms of COPD. Eur Respir Rev 1997, 7:206-210.
69. Rennard SI, Floreani AA: Pathophysiology of chronic obstructive pulmonary disease. In Asthma. Edited by Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ. New York: Lippincott-Raven; 1997:1375-1388.
70. Repine JE, Bast A, Lankhorst I, the Oxidative Stress Study Group: Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 156:341-357.
71. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Path FRC, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
72. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333:214-221.
73. Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, Shirato K: Elevated substance P in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 1995, 151:613-618.
74. Schols AMWJ, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM: Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996, 51:819-824.
75. Chanez P, Enander I, Jones I, Godard P, Bousquet J: Interleukin 8 in bronchoalveolar lavage of asthmatic and chronic bronchitis patients. Int Arch Allergy Immunol 1996, 111:83-88.
76. Cargill RI, Lipworth BJ: Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale: hemodynamic and endocrine effects. Chest 1996, 110:1220-1225.
77. Klinger JR, Cutaia M: The natriuretic peptides: clinical applications in patients with COPD. Chest 1996, 110:1136-1138.
78. Maestrelli P, Calcagni PG, Saetta M, Bertin T, Mapp CE, Sanna A, Veriter C, Fabbri LM, Stanescu D: Integrin upregulation on sputum neutrophils in smokers with chronic airway obstruction. Am J Respir Crit Care Med 1996, 154:1296-1300.
79. Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C, Bullock GR: Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996, 90:79-85.
80. Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM: Airway eosinophilia and expression of interleukin-5 protein in asthma and exacerbations of chronic bronchitis. Clin Exp Allergy 1996, 26:766-774.
81. Scalvini S, Volterrani M, Vitacca M, Clark AL, Solfrini R, Panzali AM, Ferrari R, Levi GF: Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996, 51:380-386.
82. Baudouin SV: Oedema and cor pulmonale revisited. Thorax 1997, 52:401-402.
83. Bai TR, Zhou D, Weir T, Walker B, Hegele R, Hayashi S, McKay K, Bondy G, Fong T: Substance P(NK1)- and neurokinin A(NK2)-receptor gene expression in inflammatory airway diseases. Am J Physiol 1995, 269:L309-L317.
84. Di Stefano A, Maestrelli P, Roggeri A, Turato G, Calabro S, Potena A, Mapp CE, Ciaccia A, Covacev L, Fabbri LM, Saetta M: Upregulation of adhesion molecules in the bronchial mucosa of subjects with obstructive chronic bronchitis. Am J Respir Crit Care Med 1994, 149:803-810.
85. Piperno D, Pacheco Y, Hosni R, Moliere P, Gharib C, Lagarde M, Perrin-Fayolle M: Increased plasma levels of atrial natriuretic factor, renin activity, and leukotriene C4 in chronic obstructive pulmonary disease. Chest 1993, 104:454-459.
86. Gonzàlez S, Hards J, van Eeden S, Hogg JC: The expression of adhesion molecules in cigarette smoke-induced airways obstruction. Eur Respir J 1996, 9:1995-2001.
87. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al., for the Lung Health Study Research Group: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 : the Lung Health Study. JAMA 1994, 272:1497-1505.
88. Burchfiel CM, Marcus EB, Curb JD, MacLean CJ, Vollmer WM, Johnson LM, Fong K-O, Rodriguez BL, Masaki KH, Buist AS: Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995, 151:1778-1785.
89. Kanner RE: Early intervention in chronic obstructive pulmonary disease: a review of the Lung Health Study results. Med Clin North Am 1996, 80:523-547.
90. Tarpy SP, Celli BR: Long-term oxygen therapy. N Engl J Med 1995, 333:710-714.
91. Jarvis MJ: Smoking cessation. Eur Respir Rev 1997, 7:230-234.
92. Benowitz NL: Treating tobacco addiction: nicotine or no nicotine? N Engl J Med 1997, 337:1230-1231.
93. Henningfield JE: Nicotine medications for smoking cessation. N Engl J Med 1995, 333:1196-1203.
94. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337:1195-1202.
95. Law M, Tang JL: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995, 155:1933-1941.
96. The Smoking Cessation Clinical Practice Guideline Panel and Staff: The agency for health care policy and research smoking cessation clinical practice guideline. JAMA 1996, 275:1270-1280.
97. Work Group on Nicotine Dependence: American Psychiatric Association Practice Guidelines: practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996, 153(suppl):1-31.
98. Miller NH, Smith PM, DeBusk RF, Sobel DS, Taylor CB: Smoking cessation in hospitalized patients: results of a randomized trial. Arch Intern Med 1997, 157:409-415.
99. Platt S, Tannahill A, Watson J, Fraser E: Effectiveness of antismoking telephone helpline: follow up survey. BMJ 1997, 314:1371-1375.
100. Fine MJ, Smith MA, Carson Ca, Meffe F, Sankey SS, Weissfeld LA, Detsky As, Kapoor WN: Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154:2666-2677.
101. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR: Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993, 270:1826-1831.
102. Watson PB, Town GI, Holbrook N, Dwan C, Toop LJ, Drennan CJ: Evaluation of a self-management plan for chronic obstructive pulmonary disease. Eur Respir J 1997, 10:1267-1271.
103. Donner CF, Muir JF, Rehabilitation and Chronic Care Scientific Group of the European Respiratory Society: Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Eur Respir J 1997, 10:744-757. The current guidelines of this society for pulmonary rehabilitation in COPD.
104. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C, on behalf of an international study group: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997, 10:815-821.
105. Cerveri I, Corsico A, Vitulo P, Spagnolatti L, Gualtieri G, Volpini E, Beccaria M, Zoia MC: Chronic combined therapy with inhaled salmeterol and oxytropium bromide in stable irreversible COPD [abstract]. Am J Respir Crit Care Med 1997, 155(suppl):A280.
106. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP: Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996, 51:689-693.
107. Jones PW, Bosh TK, in association with an international study group: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997, 155:1283-1289.
108. Mahler D, ZuWallach R, Rickard K, Yancey S, Wisniewsky M, Anderson W, for the COPD Clinical Investigators: Effects of salmeterol and ipratropium on dyspnea as measured by the six minute walk and baseline dyspnea index/transitionl dyspnea index (BDI/TDI) [abstract]. Am J Respir Crit Care Med 1997, 155(suppl):A278.
109. Matera MG, Caputi M, Cazzola M: A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996, 90:497-499.
110. Richard K, Wisniewski M, Anderson W: A comparison of salmeterol and ipratropium on dyspnea in Ventolin reversible and non-reversible patients with COPD [abstract]. Eur Respir J 1997, 10(suppl 25):259s.
111. Ulrik CS: Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995, 50:750-754. [See also comments on Thorax 1996, 51:110.]
112. Man GCW, Chapman KR, Ali SH, Darke AC: Sleep quality and nocturnal respiratory function with once-daily theophylline (Uniphyl) and inhaled Salbutamol in patients with COPD. Chest 1996, 110:648-653.
113. Pauwels R: The use of theophylline in chronic obstructive pulmonary disease. Clin Exp Allergy 1996, 26(suppl 2):55-59.
114. Van Schayck CP, van Grunsven PM, Dekhuijzen PNR: Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J 1996, 9:1969-1972.
115. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
116. Pauwels RA, Lofdahl CG, Pride NB, Postma DS, Laitinen LA, Ohlsson SV: European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992, 5:1254-1261.
117. Sherwood Burge P, Calverley P, for the ISOLDE Study Group: Inhaled steroids in obstructive lung disease in Europe, the ISOLDE trial; protocol and progress [abstract]. Am J Respir Crit Care Med 1994, 149(suppl):A312.
118. Brondum E, Vestbo J, Lange P, Sorensen T, Viskum K: The Copenhagen City Lung Study: a clinical trial of inhaled corticosteroids in COPD: design and progress [abstract]. Am J Respir Crit Care Med 1997, 155(suppl):A590.
119. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF: Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995, 50:834-837.
120. Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, Abel J, Niewoehner DE: Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 107:305-309.
121. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JI: Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154:407-412.
122. Niewoehner DE, Erbland ML: Systemic corticosteroids in COPD: an unresolved clinical dilemma. Chest 1996, 110:867-869.
123. Martinez J: Antibiotics and vaccination therapy in COPD. Eur Respir Rev 1997, 7:240-242.
124. Fagon JY, Chastre J: Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996, 11:109-118.
125. Saint S, Bent S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995, 273:957-960.
126. Sachs AP, Koeter GH, Groenier KH, van der Waaij, Schiphuis J, Meyboom-de Jong B: Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995, 50:758-763.